Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharmacorp Rx Inc. ( (TSE:PCRX) ) has provided an announcement.
PharmaCorp Rx Inc. has signed an investor relations agreement with LodeRock Advisors Inc. to develop and execute a 12‑month strategy aimed at strengthening its communications with analysts, investors, and the broader market. LodeRock will act as the primary investor contact, manage messaging and presentation materials, coordinate external reporting, and provide market feedback as PharmaCorp continues to expand its Canadian community pharmacy network.
Under the agreement, LodeRock will receive an initial monthly fee of $10,000 for six months and $12,500 thereafter, subject to a small annual increase and a 90‑day notice termination clause. The arm’s‑length arrangement, which remains subject to TSX Venture Exchange acceptance, underscores PharmaCorp’s efforts to professionalize its capital markets profile and support its pharmacy acquisition and growth strategy.
More about Pharmacorp Rx Inc.
PharmaCorp Rx Inc. is a Canadian pharmacy acquisition and ownership platform focused on community pharmacies under the PharmaChoice Canada banner. The company partners with pharmacists as equity owners, supports succession for retiring pharmacy operators, and is building a national network by acquiring both PharmaChoice-affiliated and independent pharmacies across Canada.
Average Trading Volume: 85,602
Technical Sentiment Signal: Sell
Current Market Cap: C$76.05M
For a thorough assessment of PCRX stock, go to TipRanks’ Stock Analysis page.